NewsBayer Presents P-III (OASIS 4) Study Data of Elinzanetant for Vasomotor Symptoms (VMS) Associated with Breast Cancer Therapies at ASCO 2025ByRidhi RastogiJune 3, 20250Comments
NewsAmgen Highlights P-III (DeLLphi-304) Trial Findings of Imdelltra for SCLC at ASCO 2025ByRidhi RastogiJune 3, 20250Comments
NewsRegeneron Enters a ~$2B In-Licensing Deal with Hansoh Pharma for HS-20094, Expanding its Obesity PortfolioByRidhi RastogiJune 3, 20250Comments
NewsModerna’s mNEXSPIKE Receives the US FDA’s Approval to Protect Against COVID-19ByRidhi RastogiJune 3, 20250Comments
NewsBMS Enters a ~$11.1B Deal with BioNTech to Jointly Develop and Commercialize BNT327ByRidhi RastogiJune 3, 20250Comments
VIEWPOINTSTakeda at ASH 2024: Phuong Khanh Morrow from Takeda in a Riveting Conversation with PharmaShotsBySaurabh ChaubeyJune 2, 20250Comments
NewsNovartis Reveals Interim P-III (PSMAddition) Trial Data of Pluvicto for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)ByRidhi RastogiJune 2, 20250Comments
NewsSandoz Launches Wyost and Jubbonti (Biosimilars, Xgeva and Prolia) in the USByRidhi RastogiJune 2, 20250Comments
